What’s New in GI Pharmacology Course

What’s New in GI Pharmacology Course

On-Demand Only

All videos will be on the conference platform October 1, 2026 – March 31, 2027.

Course Directors: Brooks D. Cash, MD, FACG, and Shailja C. Shah, MD, MPH

LECTURES WILL BE ON-DEMAND ONLY
Lecture 1 Full of Hot Air: Assessment and Management of Abdominal Bloating and Distention
Brooks D. Cash, MD, FACG
Explore the potential causes of abdominal bloating and distention, diagnostic strategies, and management.
Lecture 2 The Hepatobiliary Alphabet: Evaluation and Medical Management of PSC/PBC/AIH
Nancy S. Reau, MD, FACG
Discuss the pathophysiology, evaluation, and evidence for medical management of therapies for common autoimmune hepatobiliary diseases.
Lecture 3 Short Gut, Big Challenges: Nutritional and Medical Management of Short Bowel Syndrome
John K. DiBaise, MD, FACG
Explain the causes and effects of short bowel syndrome along with medical management, including nutritional therapies.
Lecture 4 Positioning Pharmacologic Therapies in Ulcerative Colitis: A 2026 Update
Miguel D. Regueiro, MD, FACG
Discuss the best evidence supporting the utilization of current and future pharmacologic therapies for ulcerative colitis.
Lecture 5 Best Intentions: Identifying and Navigating Drug, Herbal, and Supplement Liver Toxicity
Robert J. Fontana, MD, FACG
Identify common causes of drug induced liver toxicity and the management of drug induced liver injury.
Lecture 6 Beyond the Pain: Evaluation and Management of Chronic Pancreatitis
Jodie A. Barkin, MD, FACG
Describe the causes, work-up, and medical management, of chronic pancreatitis including treatment and surveillance of nutritional deficiencies.
Lecture 7 Eosinophilic Disorders of the UGI Tract, Esophagus and Beyond
Kathryn A. Peterson, MD, MSci
Explain the concept of eosinophil infiltration in the upper GI tract and its clinical manifestations and management.
Lecture 8 Positioning Pharmacologic Therapies in Crohn’s Disease: A 2026 Update
Gary R. Lichtenstein, MD, FACG
Discuss the best evidence supporting the utilization of current and future pharmacologic therapies for Crohn’s disease.